SecBot SecBot
SECBOTREPLAY Home › Report › PALI

PALI · Palisade Bio filed an 8-K reporting its 2026 annual meeting results,…

PALISADE BIO, INC. · 8-K filed Jun 11, 2026 at 17:23 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 11, 2026 at 17:23 ET

Palisade Bio filed an 8-K reporting its 2026 annual meeting results, including stockholder approval to increase authorized common shares from 300M to 450M, adoption of an amended equity incentive plan (42.257M shares reserved) and ESPP (837K shares reserved), and the appointment of Jordan Zwick to the board with a $566,000 RSU grant. These are routine governance and capital-structure actions that provide headroom for future equity grants but do not reflect any change in operating performance or business outlook.

  • Authorized common shares increased from 300,000,000 to 450,000,000, effective June 11, 2026.
  • Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, reserving 42,257,000 shares for future awards.
  • Stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan, reserving 837,000 shares.
  • Board expanded from five to six directors; Jordan Zwick appointed as independent director and Audit Committee member.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access